Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo.
about
Molecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia.Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.Pharmacokinetics, safety and tolerance of single- and multiple-dose adefovir dipivoxil in healthy Chinese subjects.Humanized murine model for HBV and HCV using human induced pluripotent stem cellsMutations outside the YMDD motif in the P protein can also cause DHBV resistant to Lamivudine.Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection modelCombinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy.Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.Sequential analysis of amino acid substitutions with hepatitis B virus in association with nucleoside/nucleotide analog treatment detected by deep sequencing.
P2860
Q33883921-A024DBA4-21C5-4496-9B83-F6D505154266Q34105204-E58FBBB3-A4F4-4E9E-9359-E602EC51B80FQ36024956-5AD6E2EB-87CB-4BF8-90BE-449FAA90AACAQ37065853-F8EAF5F3-2278-424E-B56D-5506D1AC8D6DQ39061363-31033777-1EA8-4C9D-9034-BE78A3B71B82Q39755479-AF160795-B3DE-4C0F-81CF-BEC5D4F0BD69Q40164099-77836ED8-FFB4-4CCC-83D6-FA001E2855F8Q40312810-DA789D76-7F6E-4E53-B025-0004BD25E170Q44738460-7D6FA715-28CC-4381-9469-1F97AEFA1877Q45227673-435AFF46-4AF6-443D-BFF6-5E5C5E7151CFQ45351100-E1AEA2F9-5905-42EE-8FAC-F9EBACC0C207
P2860
Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Duck hepatitis B virus polymer ...... capacity in vitro and in vivo.
@ast
Duck hepatitis B virus polymer ...... capacity in vitro and in vivo.
@en
type
label
Duck hepatitis B virus polymer ...... capacity in vitro and in vivo.
@ast
Duck hepatitis B virus polymer ...... capacity in vitro and in vivo.
@en
prefLabel
Duck hepatitis B virus polymer ...... capacity in vitro and in vivo.
@ast
Duck hepatitis B virus polymer ...... capacity in vitro and in vivo.
@en
P2093
P1476
Duck hepatitis B virus polymer ...... capacity in vitro and in vivo.
@en
P2093
B Seignères
I Vuillermoz
S Aguesse-Germon
P304
P356
10.1016/S0168-8278(00)00074-X
P577
2001-01-01T00:00:00Z